文献速递关节外科创伤骨科

口服利奈唑胺-利福平联合方案对假体周围关节感染高度有效:小鼠模型研究

Oral-Only Linezolid-Rifampin Is Highly Effective Compared with Other Antibiotics for Periprosthetic Joint Infection: Study of a Mouse Model.
PubMed 文献 · J Bone Joint Surg Am · 2017-01-01

该研究在小鼠耐甲氧西林金黄色葡萄球菌(MRSA)假体周围关节感染(PJI)模型中,以人体暴露剂量给药6周,评估口服与静脉单药及联合方案。结果显示口服利奈唑胺-利福平及所有静脉抗生素-利福平联合方案均无可回收细菌并减轻反应性骨改变,而所有单药治疗均未能清除感染或防止反应性骨改变。

要点

  • 口服利奈唑胺-利福平及静脉抗生素-利福平联合方案在小鼠MRSA PJI模型中均无可回收细菌。
  • 所有口服及静脉单药治疗均未能清除感染或防止反应性骨改变。
  • 口服利奈唑胺-利福平方案可能减少静脉通路并发症和医疗费用。

核心结论

  • 含利福平的联合抗生素方案(包括口服利奈唑胺-利福平及新型头孢洛林-利福平联合方案)在临床前MRSA PJI中高度有效,且疗效优于单药治疗。

研究设计与样本

  • 研究在小鼠MRSA PJI模型中以人体暴露剂量给药6周,评估口服利奈唑胺(联用或不联用口服利福平)、静脉万古霉素联用口服利福平、静脉达托霉素或头孢洛林(联用或不联用口服利福平)、口服多西环素或假治疗。

主要发现

  • 口服利奈唑胺-利福平和所有静脉抗生素-利福平联合方案均无可回收细菌,并减轻反应性骨改变。
  • 口服利奈唑胺是最有效的单药治疗,但所有口服和静脉抗生素单药治疗均未能清除感染或防止反应性骨改变。

临床怎么用

  • 作者指出,该研究为优化未来PJI抗生素治疗提供了重要的临床前证据。
  • 作者指出,口服利奈唑胺-利福平方案可能减少静脉通路并发症和医疗费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The medical treatment of periprosthetic joint infection (PJI) involves prolonged systemic antibiotic courses, often with suboptimal clinical outcomes including increased morbidity and health-care costs. Oral and intravenous monotherapies and combination antibiotic regimens were evaluated in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) PJI. METHODS: Oral linezolid with or without oral rifampin, intravenous vancomycin with oral rifampin, intravenous daptomycin or ceftaroline with or without oral rifampin, oral doxycycline, or sham treatment were administered at human-exposure doses for 6 weeks in a mouse model of PJI. Bacterial burden was assessed by in vivo bioluminescent imaging and ex vivo counting of colony-forming units (CFUs), and reactive bone changes were evaluated with radiographs and micro-computed tomography (μCT) imaging. RESULTS: Oral-only linezolid-rifampin and all intravenous antibiotic-rifampin combinations resulted in no recoverable bacteria and minimized reactive bone changes. Although oral linezolid was the most effective monotherapy, all oral and intravenous antibiotic monotherapies failed to clear infection or prevent reactive bone changes. CONCLUSIONS: Combination antibiotic-rifampin regimens, including oral-only linezolid-rifampin and the newer ceftaroline-rifampin combinations, were highly effective and more efficacious than monotherapies when used against a preclinical MRSA PJI. CLINICAL RELEVANCE: This study provides important preclinical evidence to better optimize future antibiotic therapy against PJIs. In particular, the oral-only linezolid-rifampin option might reduce venous access complications and health-care costs.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Thompson JM, Saini V, Ashbaugh AG, et al. Oral-Only Linezolid-Rifampin Is Highly Effective Compared with Other Antibiotics for Periprosthetic Joint Infection: Study of a Mouse Model. J Bone Joint Surg Am. 2017. PMID: 28419033. doi:10.2106/JBJS.16.01002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。